ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ELDN vs SLGL // RSI-14 & 200D SMA MOMENTUM

Eledon Pharmaceuticals Inc. (NASDAQ) VS. Sol-Gel Technologies Ltd. (NASDAQ) • 15-METRIC TALLY: ELDN 1 — SLGL 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ELDN
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELDN VS. SLGL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ELDN SLGL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — 0.12% — TIE /fcf-yield <GO>
Operating Margin — -38.90% — TIE /operating-margins <GO>
Net Profit Margin — -31.60% — TIE /net-margins <GO>
Revenue Growth (YoY) — 68.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 8.54 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 6/9 -5.00 SLGL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 51.0 44.4 +6.60 ELDN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $212.9M $215.1M -$2.2M SLGL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ELDN REV SLGL REV ELDN GROSS % SLGL GROSS % ELDN FCF SLGL FCF
FY 2025 $71.0M $19.4M — — -$62.3M $275.0K
FY 2024 $74.5M $11.5M — — -$47.3M -$13.9M
FY 2023 $120.4M $1.6M — — -$39.5M -$17.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELDN // BETA —
SLGL // BETA —